ArticleFrontiers in oncology2019

Selection and Validation of Induction Chemotherapy Beneficiaries Among Patients With T3N0, T3N1, T4N0 Nasopharyngeal Carcinoma Using Epstein-Barr Virus DNA: A Joint Analysis of Real-World and Clinical Trial Data.

Cheng Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.